Johnson & Johnson Reports 2021 First-Quarter Results:

- April 20th, 2021

Johnson & Johnson today announced results for first-quarter 2021. “Johnson & Johnson delivered a strong first quarter performance led by the above market growth of our Pharmaceutical business and continued recovery in Medical Devices,” said Alex Gorsky Chairman and Chief Executive Officer. “The ability to deliver these results while simultaneously advancing our robust pipeline of life-enhancing medicines, products …

Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2021. “Johnson & Johnson delivered a strong first quarter performance led by the above market growth of our Pharmaceutical business and continued recovery in Medical Devices,” said Alex Gorsky Chairman and Chief Executive Officer. “The ability to deliver these results while simultaneously advancing our robust pipeline of life-enhancing medicines, products and solutions during these times is a testament to the strength and resilience of our business and the dedication of the 135,000 employees of Johnson & Johnson who strive every day to profoundly change the trajectory of health for humanity and make healthier communities for everyone, everywhere.”

OVERALL FINANCIAL RESULTS:

FIRST QUARTER

($ in Millions, except EPS)

2021

2020

%  Change

Reported Sales

$        22,321

$        20,691

7.9%

Net Earnings

6,197

5,796

6.9

EPS (diluted)

$            2.32

$            2.17

6.9%

Non-GAAP*

FIRST QUARTER

($ in Millions, except EPS)

2021

2020

%  Change

Operational Sales 1,2

5.5%

Adjusted Operational Sales 1,3

6.0

Adjusted Net Earnings 1,4

6,924

6,154

12.5

Adjusted EPS (diluted) 1,4

$            2.59

$            2.30

12.6%

1

Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

2

Excludes the impact of translational currency

3

Excludes the net impact of acquisitions and divestitures and translational currency

4

Excludes intangible amortization expense and special items

REGIONAL SALES RESULTS:

FIRST QUARTER

%  Change

($ in Millions)

2021

2020


Reported


Operational
1,2


Currency

Adjusted
Operational 1,3

U.S.

$        11,111

$        10,699

3.9%

3.9

3.9

International

11,210

9,992

12.2

7.3

4.9

8.2

Worldwide

$        22,321

$        20,691

7.9%

5.5

2.4

6.0

1

Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

2

Excludes the impact of translational currency

3

Excludes the net impact of acquisitions and divestitures and translational currency

Note: values may have been rounded

SEGMENT SALES RESULTS:

FIRST QUARTER

%  Change

($ in Millions)

2021

2020


Reported


Operational
1,2


Currency

Adjusted
Operational 1,3

Consumer Health

$          3,543

$          3,625

(2.3)%

(3.3)

1.0

(2.9)

Pharmaceutical

12,199

11,134

9.6

7.1

2.5

7.4

Medical Devices

6,579

5,932

10.9

8.0

2.9

8.8

Worldwide

$        22,321

$        20,691

7.9%

5.5

2.4

6.0

1

Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

2

Excludes the impact of translational currency

3

Excludes the net impact of acquisitions and divestitures and translational currency

Note: values may have been rounded

FIRST-QUARTER 2021 SEGMENT COMMENTARY:

Consumer Health
Consumer Health worldwide operational sales, excluding the net impact of acquisitions and divestitures, declined 2.9%* primarily driven by negative prior year comparisons related to the COVID-19 pantry loading in Q1 2020, mainly in over-the counter products.  Partially offsetting the decline is growth in LISTERINE in oral care products, JOHNSON’S BABY in baby care products, international skin health/beauty products and NICORETTE in international over-the-counter products.

Pharmaceutical
Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 7.4%* driven by DARZALEX (daratumumab), for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis, INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. This growth was partially offset by biosimilar and generic competition, with declines primarily in REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, and U.S. ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer.

Medical Devices
Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 8.8%*, and reflects the benefit of market recovery from COVID-19 impacts in the prior year. Contributors to growth were electrophysiology products in the Interventional Solutions business, worldwide biosurgery and energy products, and international endocutters in Advanced Surgery, wound closure products in General Surgery, contact lenses and surgery in the Vision business and trauma products in Orthopaedics; partially offset by knee products in Orthopaedics.

NOTABLE NEW ANNOUNCEMENTS IN THE QUARTER:
The information contained in this section should be read in conjunction with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases available online in the Investors section of the company’s website at news releases .

Regulatory
Decisions

PONVORY (ponesimod) approved by U.S. FDA, an oral treatment for adults with relapsing
multiple sclerosis proven superior to (teriflunomide) in reducing annual relapses and brain
lesions

(press release)

Johnson & Johnson Single-Shot COVID-19 Vaccine granted conditional marketing
authorization by European Commission

(press release)

Johnson & Johnson Single-Shot COVID-19 Vaccine granted emergency use listing by the
World Health Organization

(press release)

Johnson & Johnson COVID-19 Vaccine authorized by U.S. FDA for emergency use

(press release)

SPRAVATO (Esketamine Nasal Spray) authorized in Europe for the rapid reduction of
depressive symptoms in a psychiatric emergency for patients with major depressive disorder

(press release)

MONOFOCAL INTRAOCULAR LENS – TECNIS EYHANCE AND TECNIS EYHANCE
TORIC II IOLS – receives FDA approval for a next generation treatment for cataract patients

(press release)

Regulatory
Submission

Submission of supplemental new drug application to U.S. FDA by ViiV Healthcare for
expanded use of CABENUVA (rilpivirine and cabotegravir) as an HIV treatment for use
every two months

(press release)

Other

Janssen provides update on Phase 3 ACIS Study in patients with metastatic castration-
resistant prostate cancer treated with ERLEADA (apalutamide) and ZYTIGA (abiraterone
acetate) plus prednisone combination ¹

(press release)

Johnson & Johnson announces advance purchase agreement with the African Vaccine
Acquisition Trust for the Company’s COVID-19 vaccine candidate

(press release)

PONVORY (ponesimod) receives positive CHMP opinion for the treatment of adults with
relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features

(press release)

CAR-T Therapy Ciltacabtagene Autoleucel (Cilta-cel) accepted for accelerated assessment
in Europe for the treatment of patients with heavily pretreated multiple myeloma

(press release)

1 Subsequent to the quarter

FULL-YEAR 2021 GUIDANCE:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson’s results computed in accordance with GAAP.

($ in Billions, except EPS)

January 2021

April 2021

Adjusted Operational Sales 1,2

Change vs. Prior Year

8.0% – 9.5%

8.7% – 9.9%

Operational Sales 2

Change vs. Prior Year

$88.8B – $90.0B

7.5% – 9.0%

$89.3B – $90.3B

8.2% – 9.4%

Estimated Reported Sales 3

Change vs. Prior Year

$90.5B – $91.7B

9.5% – 11.0%

$90.6B – $91.6B

9.7% – 10.9%

Adjusted Operational EPS (Diluted) 2,4

Change vs. Prior Year

$9.25 – $9.45

15.2% – 17.7%

$9.30 – $9.45

15.8% – 17.7%

Adjusted EPS (Diluted) 3,4

Change vs. Prior Year

$9.40 – $9.60

17.1% – 19.6%

$9.42 – $9.57

17.3% – 19.2%

1

Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures

2

Non-GAAP financial measure; excludes the impact of translational currency

3

Calculated using Euro Average Rate: January 2021 = $1.21 and April 2021 = $1.19 (Illustrative purposes only)

4

Non-GAAP financial measure; excludes intangible amortization expense and special items

Other modeling considerations will be provided on the webcast .

WEBCAST INFORMATION:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time . A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website . A replay and podcast will be available approximately two hours after the live webcast in the Investors section of the company’s website at events-and-presentations .

ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

NON-GAAP FINANCIAL MEASURES:
*Operational sales growth excluding the impact of translational currency, adjusted operational sales growth excluding the net impact of acquisitions and divestitures and translational currency, as well as adjusted net earnings, adjusted diluted earnings per share and adjusted operational diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investors section of the company’s website at quarterly-results .

Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly-results . These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investors section of the company’s website at quarterly-results .

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 3, 2021 including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in the Company’s most recently filed Quarterly Report on Form 10-Q and the Company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)

FIRST QUARTER

Percent Change

2021

2020

Total

Operations

Currency

Sales to customers by

segment of business

Consumer Health

U.S.

$     1,611

1,740

(7.4)

%

(7.4)

International

1,932

1,885

2.5

0.5

2.0

3,543

3,625

(2.3)

(3.3)

1.0

Pharmaceutical

U.S.

6,446

6,061

6.4

6.4

International

5,753

5,073

13.4

7.9

5.5

12,199

11,134

9.6

7.1

2.5

Medical Devices

U.S.

3,054

2,898

5.4

5.4

International

3,525

3,034

16.2

10.5

5.7

6,579

5,932

10.9

8.0

2.9

U.S.

11,111

10,699

3.9

3.9

International

11,210

9,992

12.2

7.3

4.9

Worldwide

$   22,321

20,691

7.9

%

5.5

2.4

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)

FIRST QUARTER

Percent Change

2021

2020

Total

Operations

Currency

Sales to customers by

geographic area

U.S.

$    11,111

10,699

3.9

%

3.9

Europe

5,414

4,827

12.1

4.7

7.4

Western Hemisphere excluding U.S.

1,424

1,502

(5.1)

0.0

(5.1)

Asia-Pacific, Africa

4,372

3,663

19.4

13.7

5.7

International

11,210

9,992

12.2

7.3

4.9

Worldwide

$    22,321

20,691

7.9

%

5.5

2.4

Note : Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

FIRST QUARTER

2021

2020

Percent

Percent

Percent

Increase

Amount

to Sales

Amount

to Sales

(Decrease)

Sales to customers

$      22,321

100.0

$      20,691

100.0

7.9

Cost of products sold

7,063

31.7

7,062

34.1

0.0

Gross Profit

15,258

68.3

13,629

65.9

12.0

Selling, marketing and administrative expenses

5,432

24.3

5,203

25.1

4.4

Research and development expense

3,178

14.2

2,580

12.5

23.2

Interest (income) expense, net

48

0.2

(42)

(0.2)

Other (income) expense, net

(882)

(3.9)

(679)

(3.3)

Restructuring

53

0.2

58

0.3

Earnings before provision for taxes on income

7,429

33.3

6,509

31.5

14.1

Provision for taxes on income

1,232

5.5

713

3.5

72.8

Net earnings

6,197

27.8

5,796

28.0

6.9

Net earnings per share (Diluted)

$          2.32

$          2.17

6.9

Average shares outstanding (Diluted)

2,672.7

2,671.0

Effective tax rate

16.6

%

11.0

%

Adjusted earnings before provision for taxes and net earnings (1)

Earnings before provision for taxes on income

$        8,291

37.1

$        7,244

35.0

14.5

Net earnings

$        6,924

31.0

$        6,154

29.7

12.5

Net earnings per share (Diluted)

$          2.59

$          2.30

12.6

Effective tax rate

16.5

%

15.0

%

(1) See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries

Reconciliation of Non-GAAP Financial Measures

First Quarter

(Dollars in Millions Except Per Share Data)

2021

2020

Net Earnings, after tax- as reported

$6,197

$5,796

Pre-tax Adjustments

Intangible Asset Amortization expense

1,215

1,118

Litigation expense

120

Restructuring related

104

118

Acquisition, integration and divestiture related 1

(538)

(962)

Unrealized (gains)/losses on securities

35

327

Medical Device Regulation

46

14

Tax Adjustments

Tax impact on special item adjustments 2

(113)

(267)

Tax legislation and other tax related

(22)

(110)

Adjusted Net Earnings, after tax

$6,924

$6,154

Average shares outstanding (Diluted)

2,672.7

2,671.0

Adjusted net earnings per share (Diluted)

$2.59

$2.30

Operational adjusted net earnings per share (Diluted)

$2.49

Notes:

1

Acquisition, integration and divestiture related for the first quarter of 2021 primarily includes the gain on the divestiture of 2
Pharmaeutical brands outside of the U.S.  The first quarter of 2020 primarily includes a $983M Contingent Consideration reversal
related to the timing of certain developmental milestones associated with the Auris Health acquisition.

2

The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax
special items in arriving at adjusted earnings.

Johnson & Johnson and Subsidiaries

Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth

FIRST QUARTER 2021 ACTUAL vs. 2020 ACTUAL

Segments

Consumer Health

Pharmaceutical

Medical Devices

Total

WW As Reported

(2.3)%

9.6%

10.9%

7.9%

U.S.

(7.4)%

6.4%

5.4%

3.9%

International

2.5%

13.4%

16.2%

12.2%

WW Currency

1.0

2.5

2.9

2.4

U.S.

International

2.0

5.5

5.7

4.9

WW Operational

(3.3)%

7.1%

8.0%

5.5%

U.S.

(7.4)%

6.4%

5.4%

3.9%

International

0.5%

7.9%

10.5%

7.3%

General Surgery

Advanced Sterilization Products

0.6

0.2

U.S.

0.0

0.0

International

1.2

0.4

All Other Acquisitions and Divestitures

0.4

0.3

0.1

0.3

U.S.

0.5

(0.2)

0.2

0.0

International

0.4

0.9

0.0

0.5

WW Adjusted Operational

(2.9)%

7.4%

8.8%

6.0%

U.S.

(6.9)%

6.2%

5.6%

3.9%

International

0.9%

8.8%

11.8%

8.2%

Note: Percentages are based on actual, non-rounded figures and may not sum

REPORTED SALES vs. PRIOR PERIOD ($MM)

FIRST QUARTER

% Change

2021

2020

Reported

Operational (1)

Currency

CONSUMER HEALTH SEGMENT (2)

OTC

US

$              599

689

-13.0%

-13.0%

Intl

575

659

-12.8%

-16.6%

3.8%

WW

1,175

1,348

-12.9%

-14.8%

1.9%

SKIN HEALTH / BEAUTY

US

634

659

-3.9%

-3.9%

Intl

529

458

15.7%

12.3%

3.4%

WW

1,163

1,117

4.1%

2.8%

1.3%

ORAL CARE

US

163

176

-7.2%

-7.2%

Intl

254

219

16.0%

13.9%

2.1%

WW

417

395

5.7%

4.5%

1.2%

BABY CARE

US

96

92

4.2%

4.2%

Intl

293

269

8.9%

11.3%

-2.4%

WW

389

361

7.7%

9.5%

-1.8%

WOMEN’S HEALTH

US

3

4

-25.8%

-25.8%

Intl

219

228

-3.9%

-2.2%

-1.7%

WW

222

232

-4.3%

-2.6%

-1.7%

WOUND CARE / OTHER

US

115

119

-3.0%

-3.0%

Intl

61

52

17.6%

14.2%

3.4%

WW

177

171

3.3%

2.2%

1.1%

TOTAL CONSUMER HEALTH

US

1,611

1,740

-7.4%

-7.4%

Intl

1,932

1,885

2.5%

0.5%

2.0%

WW

$           3,543

3,625

-2.3%

-3.3%

1.0%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD ($MM)

FIRST QUARTER

% Change

PHARMACEUTICAL SEGMENT (2,3)

2021

2020

Reported

Operational (1)

Currency

IMMUNOLOGY

US

$           2,413

2,410

0.1%

0.1%

Intl

1,501

1,228

22.3%

15.9%

6.4%

WW

3,914

3,638

7.6%

5.5%

2.1%

REMICADE

US

489

625

-21.7%

-21.7%

US Exports (4)

57

110

-48.4%

-48.4%

Intl

232

256

-9.4%

-12.1%

2.7%

WW

777

990

-21.5%

-22.2%

0.7%

SIMPONI / SIMPONI ARIA

US

255

272

-5.9%

-5.9%

Intl

307

258

18.9%

13.8%

5.1%

WW

562

529

6.2%

3.7%

2.5%

STELARA

US

1,331

1,217

9.4%

9.4%

Intl

817

603

35.6%

27.6%

8.0%

WW

2,148

1,819

18.1%

15.4%

2.7%

TREMFYA

US

274

187

46.3%

46.3%

Intl

143

109

32.0%

23.1%

8.9%

WW

418

296

41.0%

37.8%

3.2%

OTHER IMMUNOLOGY

US

7

*

*

Intl

2

3

-38.4%

-36.3%

-2.1%

WW

8

3

*

*

*

INFECTIOUS DISEASES

US

512

436

17.4%

17.4%

Intl

494

483

2.3%

-2.2%

4.5%

WW

1,007

920

9.5%

7.1%

2.4%

COVID-19 VACCINE

US

100

*

*

Intl

WW

100

*

*

EDURANT / rilpivirine

US

10

12

-12.3%

-12.3%

Intl

233

212

9.8%

0.9%

8.9%

WW

243

224

8.6%

0.2%

8.4%

PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA

US

380

396

-3.8%

-3.8%

Intl

166

184

-9.9%

-10.4%

0.5%

WW

546

579

-5.8%

-5.9%

0.1%

OTHER INFECTIOUS DISEASES

US

21

29

-27.0%

-27.0%

Intl

96

87

9.7%

7.4%

2.3%

WW

117

116

0.6%

-1.2%

1.8%

REPORTED SALES vs. PRIOR PERIOD ($MM)

FIRST QUARTER

% Change

2021

2020

Reported

Operational (1)

Currency

NEUROSCIENCE

US

771

748

3.2%

3.2%

Intl

949

910

4.3%

0.4%

3.9%

WW

1,721

1,658

3.8%

1.6%

2.2%

CONCERTA / Methylphenidate

US

47

52

-9.6%

-9.6%

Intl

123

118

4.5%

-0.4%

4.9%

WW

171

171

0.2%

-3.2%

3.4%

INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA

US

589

544

8.3%

8.3%

Intl

376

339

11.0%

4.5%

6.5%

WW

965

883

9.4%

6.9%

2.5%

RISPERDAL CONSTA

US

67

76

-11.8%

-11.8%

Intl

89

94

-4.8%

-8.8%

4.0%

WW

157

170

-7.9%

-10.1%

2.2%

OTHER NEUROSCIENCE

US

67

75

-9.8%

-9.8%

Intl

361

360

0.2%

-0.9%

1.1%

WW

428

435

-1.5%

-2.5%

1.0%

ONCOLOGY

US

1,377

1,175

17.2%

17.2%

Intl

2,193

1,839

19.3%

12.9%

6.4%

WW

3,570

3,013

18.5%

14.6%

3.9%

DARZALEX

US

691

463

49.2%

49.2%

Intl

674

474

42.2%

35.3%

6.9%

WW

1,365

937

45.6%

42.2%

3.4%

ERLEADA

US

171

119

44.0%

44.0%

Intl

90

24

*

*

*

WW

261

143

82.8%

79.7%

3.1%

IMBRUVICA

US

444

432

2.8%

2.8%

Intl

680

599

13.5%

7.6%

5.9%

WW

1,125

1,031

9.0%

5.6%

3.4%

ZYTIGA / abiraterone acetate

US

50

139

-64.2%

-64.2%

Intl

588

552

6.6%

0.0%

6.6%

WW

638

690

-7.6%

-12.9%

5.3%

OTHER ONCOLOGY (5)

US

21

22

-5.1%

-5.1%

Intl

161

190

-15.3%

-19.3%

4.0%

WW

182

212

-14.2%

-17.9%

3.7%

REPORTED SALES vs. PRIOR PERIOD ($MM)

FIRST QUARTER

% Change

2021

2020

Reported

Operational (1)

Currency

PULMONARY HYPERTENSION

US

573

486

18.0%

18.0%

Intl

288

260

10.8%

5.6%

5.2%

WW

861

745

15.5%

13.7%

1.8%

OPSUMIT

US

272

229

18.5%

18.5%

Intl

179

160

11.5%

6.3%

5.2%

WW

450

389

15.6%

13.5%

2.1%

UPTRAVI

US

259

212

21.9%

21.9%

Intl

46

38

23.0%

15.7%

7.3%

WW

305

250

22.0%

20.9%

1.1%

OTHER PULMONARY HYPERTENSION

US

42

44

-3.5%

-3.5%

Intl

63

62

1.4%

-2.1%

3.5%

WW

105

106

-0.6%

-2.7%

2.1%

CARDIOVASCULAR / METABOLISM / OTHER

US

799

806

-0.9%

-0.9%

Intl

328

354

-7.2%

-11.3%

4.1%

WW

1,127

1,160

-2.8%

-4.1%

1.3%

XARELTO

US

589

527

11.7%

11.7%

Intl

WW

589

527

11.7%

11.7%

INVOKANA / INVOKAMET

US

87

117

-26.1%

-26.1%

Intl

63

58

9.2%

4.2%

5.0%

WW

150

175

-14.4%

-16.1%

1.7%

PROCRIT / EPREX

US

62

76

-18.3%

-18.3%

Intl

64

79

-18.1%

-22.2%

4.1%

WW

127

155

-18.2%

-20.3%

2.1%

OTHER

US

60

85

-28.8%

-28.8%

Intl

201

217

-7.7%

-11.5%

3.8%

WW

261

302

-13.6%

-16.4%

2.8%

TOTAL PHARMACEUTICAL

US

6,446

6,061

6.4%

6.4%

Intl

5,753

5,073

13.4%

7.9%

5.5%

WW

$         12,199

11,134

9.6%

7.1%

2.5%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD ($MM)

FIRST QUARTER

% Change

MEDICAL DEVICES SEGMENT (2)

2021

2020

Reported

Operational (1)

Currency

INTERVENTIONAL SOLUTIONS

US

$              434

365

19.0%

19.0%

Intl

514

362

42.0%

34.0%

8.0%

WW

949

727

30.4%

26.4%

4.0%

ORTHOPAEDICS

US

1,249

1,250

-0.1%

-0.1%

Intl

864

788

9.7%

3.1%

6.6%

WW

2,113

2,038

3.7%

1.2%

2.5%

HIPS

US

210

206

2.4%

2.4%

Intl

146

132

11.2%

4.5%

6.7%

WW

357

337

5.8%

3.2%

2.6%

KNEES

US

185

214

-13.5%

-13.5%

Intl

132

130

2.0%

-4.1%

6.1%

WW

317

343

-7.6%

-9.9%

2.3%

TRAUMA

US

450

407

10.7%

10.7%

Intl

282

247

14.4%

7.7%

6.7%

WW

733

654

12.1%

9.5%

2.6%

SPINE, SPORTS & OTHER

US

403

423

-4.8%

-4.8%

Intl

303

280

8.4%

1.7%

6.7%

WW

706

703

0.4%

-2.2%

2.6%

REPORTED SALES vs. PRIOR PERIOD ($MM)

FIRST QUARTER

% Change

2021

2020

Reported

Operational (1)

Currency

SURGERY

US

898

844

6.5%

6.5%

Intl

1,474

1,257

17.3%

11.7%

5.6%

WW

2,372

2,100

12.9%

9.6%

3.3%

ADVANCED

US

405

381

6.5%

6.5%

Intl

713

567

25.7%

19.5%

6.2%

WW

1,118

948

18.0%

14.3%

3.7%

GENERAL

US

493

463

6.5%

6.5%

Intl

761

690

10.3%

5.3%

5.0%

WW

1,254

1,153

8.8%

5.8%

3.0%

VISION

US

472

439

7.4%

7.4%

Intl

673

628

7.3%

3.9%

3.4%

WW

1,145

1,067

7.3%

5.4%

1.9%

CONTACT LENSES / OTHER

US

371

346

7.2%

7.2%

Intl

486

467

4.0%

0.9%

3.1%

WW

857

814

5.3%

3.5%

1.8%

SURGICAL

US

101

93

8.2%

8.2%

Intl

187

160

17.0%

12.9%

4.1%

WW

288

253

13.7%

11.2%

2.5%

TOTAL MEDICAL DEVICES

US

3,054

2,898

5.4%

5.4%

Intl

3,525

3,034

16.2%

10.5%

5.7%

WW

$           6,579

5,932

10.9%

8.0%

2.9%

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely.

* Percentage greater than 100% or not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Certain prior year amounts have been reclassified to conform to current year product disclosures

(4) Reported as U.S. sales

(5) Refer to supplemental schedule

Supplemental Sales Information

(Dollars in Millions)

Prior quarter amounts have been reclassified to

conform to current quarter product disclosure

2019

2020

2020

PHARMACEUTICAL SEGMENT (1)

Full Year

Q1

Q2

Q3

Q4

Full Year

Oncology

OTHER ONCOLOGY (2)

US

70

22

20

21

20

83

Intl

1,087

190

185

181

183

738

WW

1,158

212

204

203

202

821

Note : Columns and rows within tables may not add due to rounding.

(1) Unaudited

(2) Other Oncology is inclusive of VELCADE, which was previously disclosed separately

Cision View original content to download multimedia: http://www.prnewswire.com/news-releases/johnson–johnson-reports-2021-first-quarter-results-301272130.html

SOURCE Johnson & Johnson

News Provided by PR Newswire via QuoteMedia

  Life Science and Healthcare Investing report cover

Life Science and Healthcare Investing in 2021

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!
 

Tags

Leave a Reply